Index,NCTId,Condition,Change,Reference,Variable,Timepoint,Endpoint Art
0,NCT04984707,Androgenetic Alopecia,Not Mentioned,Not Mentioned,Treatment-Emergent Adverse Events (Teae),3 Days,Primary Endpoint
1,NCT04984707,Androgenetic Alopecia,Not Mentioned,Not Mentioned,Treatment-Emergent Adverse Events (Teae),3 Days,Primary Endpoint
2,NCT04984707,Androgenetic Alopecia,Not Mentioned,Not Mentioned,Treatment-Emergent Adverse Events (Teae),3 Days,Primary Endpoint
3,NCT04984707,Androgenetic Alopecia,Not Mentioned,Not Mentioned,"Treatment-Emergent Adverse Events (Teae), Lab Tests",3 Days,Primary Endpoint
4,NCT04984707,Androgenetic Alopecia,Not Mentioned,Not Mentioned,Study Drug Related Teaes,3 Days,Primary Endpoint
5,NCT04984707,Androgenetic Alopecia,Auc,"Infinite Time, Time, Total Exposure(Aucinf)","Infinite Time, Time, Total Exposure(Aucinf)",48 Hours,Secondary Endpoint
6,NCT04984707,Androgenetic Alopecia,Auc,Time,Not Mentioned,48 Hours,Secondary Endpoint
7,NCT04984707,Androgenetic Alopecia,Not Mentioned,Not Mentioned,Not Mentioned,48 Hours,Secondary Endpoint
8,NCT04984707,Androgenetic Alopecia,Not Mentioned,Not Mentioned,Time At Which Cmax Was First Observed(Tmax),48 Hours,Secondary Endpoint
9,NCT04984707,Androgenetic Alopecia,Not Mentioned,Not Mentioned,Half Life（T½,48 Hours,Secondary Endpoint
10,NCT04984707,Androgenetic Alopecia,F),Not Mentioned,Not Mentioned,48 Hours,Secondary Endpoint
11,NCT04984707,Androgenetic Alopecia,/F),Not Mentioned,Not Mentioned,48 Hours,Secondary Endpoint
12,NCT04984707,Androgenetic Alopecia,Elimination Rate,Not Mentioned,Not Mentioned,48 Hours,Secondary Endpoint
13,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Global Cognition,At Baseline.,Primary Endpoint
14,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Global Cognition,Immediately After Intervention.,Primary Endpoint
15,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Global Cognition,At 4 Weeks After Intervention.,Primary Endpoint
16,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Global Cognition,At 12 Weeks After Intervention.,Primary Endpoint
17,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Global Cognition,At 24 Weeks After Intervention.,Primary Endpoint
18,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Memory,At Baseline.,Primary Endpoint
19,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Memory,Immediately After Intervention.,Primary Endpoint
20,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Memory,At 4 Weeks After Intervention.,Primary Endpoint
21,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Memory,At 12 Weeks After Intervention.,Primary Endpoint
22,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Memory,At 24 Weeks After Intervention.,Primary Endpoint
23,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Attention,At Baseline.,Primary Endpoint
24,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Attention,Immediately After Intervention.,Primary Endpoint
25,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Attention,At 4 Weeks After Intervention.,Primary Endpoint
26,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Attention,At 12 Weeks After Intervention.,Primary Endpoint
27,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Attention,At 24 Weeks After Intervention.,Primary Endpoint
28,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Visual/Spatial Function,At Baseline.,Primary Endpoint
29,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Visual/Spatial Function,Immediately After Intervention.,Primary Endpoint
30,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Visual/Spatial Function,At 4 Weeks After Intervention.,Primary Endpoint
31,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Visual/Spatial Function,At 12 Weeks After Intervention.,Primary Endpoint
32,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Visual/Spatial Function,At 24 Weeks After Intervention.,Primary Endpoint
33,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Executive Function,At Baseline.,Primary Endpoint
34,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Executive Function,Immediately After Intervention.,Primary Endpoint
35,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Executive Function,At 4 Weeks After Intervention.,Primary Endpoint
36,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Executive Function,At 12 Weeks After Intervention.,Primary Endpoint
37,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Executive Function,At 24 Weeks After Intervention.,Primary Endpoint
38,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Not Mentioned,At Baseline.,Secondary Endpoint
39,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Not Mentioned,Immediately After Intervention.,Secondary Endpoint
40,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Not Mentioned,At 4 Weeks After Intervention.,Secondary Endpoint
41,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Not Mentioned,At 12 Weeks After Intervention.,Secondary Endpoint
42,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Not Mentioned,At 24 Weeks After Intervention.,Secondary Endpoint
43,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Not Mentioned,At Baseline.,Secondary Endpoint
44,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Not Mentioned,Immediately After Intervention.,Secondary Endpoint
45,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Not Mentioned,At 4 Weeks After Intervention.,Secondary Endpoint
46,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Not Mentioned,At 12 Weeks After Intervention.,Secondary Endpoint
47,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Not Mentioned,At 24 Weeks After Intervention.,Secondary Endpoint
48,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Not Mentioned,At Baseline.,Secondary Endpoint
49,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Not Mentioned,Immediately After Intervention.,Secondary Endpoint
50,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Not Mentioned,At 4 Weeks After Intervention.,Secondary Endpoint
51,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Not Mentioned,At 12 Weeks After Intervention.,Secondary Endpoint
52,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Not Mentioned,At 24 Weeks After Intervention.,Secondary Endpoint
53,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Gwbs),Not Mentioned,Not Mentioned,At Baseline.,Secondary Endpoint
54,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Gwbs),Not Mentioned,Not Mentioned,Immediately After Intervention.,Secondary Endpoint
55,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Gwbs),Not Mentioned,Not Mentioned,At 4 Weeks After Intervention.,Secondary Endpoint
56,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Gwbs),Not Mentioned,Not Mentioned,At 12 Weeks After Intervention.,Secondary Endpoint
57,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Gwbs),Not Mentioned,Not Mentioned,At 24 Weeks After Intervention.,Secondary Endpoint
58,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Not Mentioned,At Baseline.,Secondary Endpoint
59,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Not Mentioned,Immediately After Intervention.,Secondary Endpoint
60,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Not Mentioned,At 4 Weeks After Intervention.,Secondary Endpoint
61,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Not Mentioned,At 12 Weeks After Intervention.,Secondary Endpoint
62,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Not Mentioned,At 24 Weeks After Intervention.,Secondary Endpoint
63,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Not Mentioned,At Baseline.,Secondary Endpoint
64,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Not Mentioned,Immediately After Intervention.,Secondary Endpoint
65,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Not Mentioned,At 4 Weeks After Intervention.,Secondary Endpoint
66,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Not Mentioned,At 12 Weeks After Intervention.,Secondary Endpoint
67,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Not Mentioned,At 24 Weeks After Intervention.,Secondary Endpoint
68,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Quality Of Life-Eq5D-Utility,At Baseline.,Secondary Endpoint
69,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Quality Of Life-Eq5D-Utility,Immediately After Intervention.,Secondary Endpoint
70,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Quality Of Life-Eq5D-Utility,At 4 Weeks After Intervention.,Secondary Endpoint
71,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Quality Of Life-Eq5D-Utility,At 12 Weeks After Intervention.,Secondary Endpoint
72,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Quality Of Life-Eq5D-Utility,At 24 Weeks After Intervention.,Secondary Endpoint
73,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Quality Of Life-Eq5D-Visual Analogue Scale,At Baseline.,Secondary Endpoint
74,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Quality Of Life-Eq5D-Visual Analogue Scale,Immediately After Intervention.,Secondary Endpoint
75,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Quality Of Life-Eq5D-Visual Analogue Scale,At 4 Weeks After Intervention.,Secondary Endpoint
76,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Quality Of Life-Eq5D-Visual Analogue Scale,At 12 Weeks After Intervention.,Secondary Endpoint
77,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Quality Of Life-Eq5D-Visual Analogue Scale,At 24 Weeks After Intervention.,Secondary Endpoint
78,NCT04984564,Educational Problems,Not Mentioned,"Simulator Based Learning, Feedback Of Individual, Training On Virtual","Simulator Based Learning, Feedback Of Individual, Training On Virtual",Survey Was Conducted From August To July 2020. Subjects Had Two Month Period To Respond.,Primary Endpoint
79,NCT04984564,Educational Problems,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
80,NCT04984135,"Coronary Stenosis, Drug-Coated Balloon",In-Segment Late Lumen Loss,Not Mentioned,Not Mentioned,6 Months,Primary Endpoint
81,NCT04984135,"Coronary Stenosis, Drug-Coated Balloon",Not Mentioned,Not Mentioned,Target Lesion Failure,6 Months,Secondary Endpoint
82,NCT04983849,"Mmp8, Mmp9, Il1, Il6, Il8, Il17, Tnf Alfa, Rank-L, Opg, Cal, Ppd, Gi, Fmps, Fmbs",Mmp8,Not Mentioned,Not Mentioned,Baseline - 1 Week,Primary Endpoint
83,NCT04983849,"Mmp8, Mmp9, Il1, Il6, Il8, Il17, Tnf Alfa, Rank-L, Opg, Cal, Ppd, Gi, Fmps, Fmbs",Tnf Alfa,Not Mentioned,Not Mentioned,Baseline - 1 Week,Primary Endpoint
84,NCT04983849,"Mmp8, Mmp9, Il1, Il6, Il8, Il17, Tnf Alfa, Rank-L, Opg, Cal, Ppd, Gi, Fmps, Fmbs",Not Mentioned,Not Mentioned,Not Mentioned,Baseline - 1 Week,Primary Endpoint
85,NCT04983849,"Mmp8, Mmp9, Il1, Il6, Il8, Il17, Tnf Alfa, Rank-L, Opg, Cal, Ppd, Gi, Fmps, Fmbs",Not Mentioned,Not Mentioned,Not Mentioned,Baseline - 1 Week,Primary Endpoint
86,NCT04983849,"Mmp8, Mmp9, Il1, Il6, Il8, Il17, Tnf Alfa, Rank-L, Opg, Cal, Ppd, Gi, Fmps, Fmbs",Not Mentioned,Not Mentioned,Cal,Baseline - 1 Week,Secondary Endpoint
87,NCT04983849,"Mmp8, Mmp9, Il1, Il6, Il8, Il17, Tnf Alfa, Rank-L, Opg, Cal, Ppd, Gi, Fmps, Fmbs",Not Mentioned,Not Mentioned,Not Mentioned,Baseline - 1 Week,Secondary Endpoint
88,NCT04983849,"Mmp8, Mmp9, Il1, Il6, Il8, Il17, Tnf Alfa, Rank-L, Opg, Cal, Ppd, Gi, Fmps, Fmbs",Gi,Not Mentioned,Not Mentioned,Baseline - 1 Week,Secondary Endpoint
89,NCT04983849,"Mmp8, Mmp9, Il1, Il6, Il8, Il17, Tnf Alfa, Rank-L, Opg, Cal, Ppd, Gi, Fmps, Fmbs",Not Mentioned,Not Mentioned,Not Mentioned,Baseline - 1 Week,Secondary Endpoint
90,NCT04983849,"Mmp8, Mmp9, Il1, Il6, Il8, Il17, Tnf Alfa, Rank-L, Opg, Cal, Ppd, Gi, Fmps, Fmbs",Not Mentioned,Not Mentioned,Not Mentioned,Baseline - 1 Week,Secondary Endpoint
91,NCT04983719,"Atypical, Myoma",Not Mentioned,"Video, Evaluation","Video, Evaluation",Day 1,Primary Endpoint
92,NCT04983719,"Atypical, Myoma",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
93,NCT04983641,Orthopedic Disorder,Clinic Visit,Not Mentioned,Not Mentioned,1 Week,Primary Endpoint
94,NCT04983641,Orthopedic Disorder,Clinic Visit,Not Mentioned,Not Mentioned,1 Week,Primary Endpoint
95,NCT04983641,Orthopedic Disorder,Clinic Visit,Not Mentioned,Overall (Pre-Visit,1 Week,Primary Endpoint
96,NCT04983641,Orthopedic Disorder,Not Mentioned,Not Mentioned,Time To Pre-Visit Promis,1 Week,Secondary Endpoint
97,NCT04983641,Orthopedic Disorder,Not Mentioned,Patient Demographics,Not Mentioned,1 Week,Secondary Endpoint
98,NCT04983524,"Post-Operative Pain, Chronic, Necrotic Pulp",Not Mentioned,Not Mentioned,Not Mentioned,One Week. Line Of 10 Points,Primary Endpoint
99,NCT04983524,"Post-Operative Pain, Chronic, Necrotic Pulp",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
100,NCT04983459,"Prostatic Neoplasms, Recurrence",Rate Per Patient,"Detection, Detection, Biochemical Recurrence, Pet-Psma","Detection, Detection, Biochemical Recurrence, Pet-Psma",12 Months,Primary Endpoint
101,NCT04983459,"Prostatic Neoplasms, Recurrence",Biochemical Recurrence,"Detection, Detection, Psma-Pet","Detection, Detection, Psma-Pet",12 Months,Secondary Endpoint
102,NCT04983381,"Pelvic Pain, Pelvic Floor; Relaxation",Not Mentioned,Not Mentioned,Pelvic Examination,6 Months,Primary Endpoint
103,NCT04983381,"Pelvic Pain, Pelvic Floor; Relaxation",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
104,NCT04983212,Peri-Implantitis,Not Mentioned,Not Mentioned,Prevalence,01/01/2015 - 01/01/2020,Primary Endpoint
105,NCT04983212,Peri-Implantitis,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
106,NCT04983160,Chronic Kidney Disease,Not Mentioned,Not Mentioned,"Microparticles Derived From Endothelial Cells, Circulating Endothelial Progenitor Cells Concentration","Data Collected After 4 Weeks, 8 Weeks And 12 Weeks.",Primary Endpoint
107,NCT04983160,Chronic Kidney Disease,Not Mentioned,Not Mentioned,Not Mentioned,"After Patient Visit (0 Weeks, 4, 8 And 12 Weeks)",Secondary Endpoint
108,NCT04983160,Chronic Kidney Disease,Not Mentioned,Not Mentioned,Not Mentioned,"After Patient Visit (0 Weeks, 4, 8 And 12 Weeks)",Secondary Endpoint
109,NCT04983160,Chronic Kidney Disease,Not Mentioned,Not Mentioned,Not Mentioned,"After Patient Visit (0 Weeks, 4, 8 And 12 Weeks)",Secondary Endpoint
110,NCT04983160,Chronic Kidney Disease,Not Mentioned,Not Mentioned,Blood Pressure,"Each Visit (0 Weeks, 4 Weeks, 8 Weeks And 12 Weeks) For 24 Hours",Secondary Endpoint
111,NCT04983160,Chronic Kidney Disease,Not Mentioned,Not Mentioned,Not Mentioned,"After Patient Visit (0 Weeks, 4 Weeks, 8 Weeks And 12 Weeks)",Secondary Endpoint
112,NCT04983160,Chronic Kidney Disease,Not Mentioned,Not Mentioned,Not Mentioned,"Daily, Using First Urine Of The Day As A Sample.",Secondary Endpoint
113,NCT04983147,Obesity,Not Mentioned,Health Belief Model Scale,Not Mentioned,Up To 12 Weeks,Primary Endpoint
114,NCT04983147,Obesity,Not Mentioned,"Importance, Health Belief Model Scale",Not Mentioned,Up To 12 Weeks,Primary Endpoint
115,NCT04983147,Obesity,Not Mentioned,"Health Belief Model Scale, Perceived Sensitivity",Not Mentioned,Up To 12 Weeks,Primary Endpoint
116,NCT04983147,Obesity,Not Mentioned,"Perceived Severity, Health Belief Model Scale",Not Mentioned,Up To 12 Weeks,Primary Endpoint
117,NCT04983147,Obesity,Not Mentioned,"Health Belief Model Scale, Perceived Benefit",Not Mentioned,Up To 12 Weeks,Primary Endpoint
118,NCT04983147,Obesity,Not Mentioned,"Perceived Barrier, Health Belief Model Scale","Perceived Barrier, Health Belief Model Scale",Up To 12 Weeks,Primary Endpoint
119,NCT04983147,Obesity,Not Mentioned,Not Mentioned,Not Mentioned,Up To 12 Weeks,Primary Endpoint
120,NCT04983147,Obesity,Weighing Machine,Not Mentioned,Not Mentioned,Up To 12 Weeks,Primary Endpoint
121,NCT04983147,Obesity,Not Mentioned,Not Mentioned,Not Mentioned,Up To 12 Weeks,Primary Endpoint
122,NCT04983147,Obesity,Not Mentioned,Health Belief Model Scale,Not Mentioned,"Through Study Completion, An Average Of 1 Year",Secondary Endpoint
123,NCT04983147,Obesity,Not Mentioned,"Importance, Health Belief Model Scale",Not Mentioned,"Through Study Completion, An Average Of 1 Year",Secondary Endpoint
124,NCT04983147,Obesity,Not Mentioned,"Health Belief Model Scale, Perceived Sensitivity",Not Mentioned,"Through Study Completion, An Average Of 1 Year",Secondary Endpoint
125,NCT04983147,Obesity,Not Mentioned,"Perceived Severity, Health Belief Model Scale",Not Mentioned,"Through Study Completion, An Average Of 1 Year",Secondary Endpoint
126,NCT04983147,Obesity,Not Mentioned,"Health Belief Model Scale, Perceived Benefit",Not Mentioned,"Through Study Completion, An Average Of 1 Year",Secondary Endpoint
127,NCT04983147,Obesity,Not Mentioned,"Perceived Barrier, Health Belief Model Scale","Perceived Barrier, Health Belief Model Scale","Through Study Completion, An Average Of 1 Year",Secondary Endpoint
128,NCT04983147,Obesity,Not Mentioned,Not Mentioned,Not Mentioned,"Through Study Completion, An Average Of 1 Year",Secondary Endpoint
129,NCT04983147,Obesity,Weighing Machine,Not Mentioned,Not Mentioned,"Through Study Completion, An Average Of 1 Year",Secondary Endpoint
130,NCT04983147,Obesity,Not Mentioned,Not Mentioned,Not Mentioned,"Through Study Completion, An Average Of 1 Year",Secondary Endpoint
131,NCT04983056,Fournier Gangrene,Number Of Patients,Not Mentioned,Not Mentioned,Six Months,Primary Endpoint
132,NCT04983056,Fournier Gangrene,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
133,NCT04982978,Vaping Related Disorder,Not Mentioned,Not Mentioned,"Effect Of Threat Appraisal, Vaping Intention",6-Weeks,Primary Endpoint
134,NCT04982978,Vaping Related Disorder,Perceived Vulnerability,"Effect, Intention","Effect, Intention",6-Weeks,Secondary Endpoint
135,NCT04982978,Vaping Related Disorder,Not Mentioned,"Effect, Intention","Effect, Intention",6-Weeks,Secondary Endpoint
136,NCT04982874,Drug Use,Not Mentioned,Geometric Mean,Not Mentioned,1 Month,Primary Endpoint
137,NCT04982874,Drug Use,90% Confidence Intervals,Not Mentioned,Not Mentioned,1 Month,Primary Endpoint
138,NCT04982874,Drug Use,Not Mentioned,Not Mentioned,Not Mentioned,1 Month,Secondary Endpoint
139,NCT04982874,Drug Use,Not Mentioned,Not Mentioned,Not Mentioned,1 Month,Secondary Endpoint
140,NCT04982861,Drug Use,Not Mentioned,Geometric Mean,Not Mentioned,3 Months,Primary Endpoint
141,NCT04982861,Drug Use,90% Confidence Intervals,Not Mentioned,Not Mentioned,3 Months,Primary Endpoint
142,NCT04982861,Drug Use,Not Mentioned,Not Mentioned,Not Mentioned,3 Months,Secondary Endpoint
143,NCT04982861,Drug Use,Not Mentioned,Not Mentioned,Not Mentioned,3 Months,Secondary Endpoint
144,NCT04982809,Interstitial Lung Disease,Not Mentioned,Not Mentioned,Lungen - 6 (Kl-6),3 Months,Primary Endpoint
145,NCT04982809,Interstitial Lung Disease,Not Mentioned,Not Mentioned,Not Mentioned,3 Months,Secondary Endpoint
146,NCT04982809,Interstitial Lung Disease,Not Mentioned,Not Mentioned,Not Mentioned,3 Months,Secondary Endpoint
147,NCT04982809,Interstitial Lung Disease,Not Mentioned,Not Mentioned,Not Mentioned,3 Months,Secondary Endpoint
148,NCT04982809,Interstitial Lung Disease,Not Mentioned,Not Mentioned,Not Mentioned,3 Months,Secondary Endpoint
149,NCT04982809,Interstitial Lung Disease,Not Mentioned,Not Mentioned,Not Mentioned,3 Months,Secondary Endpoint
150,NCT04982601,"Temporomandibular Disorders, Myofascial Pain Dysfunction Syndrome, Temporomandibular Joint Pain, Range Of Motion, Yoga, Quality Of Life",Scale(Vas),Not Mentioned,Analog,6 Weeks,Primary Endpoint
151,NCT04982601,"Temporomandibular Disorders, Myofascial Pain Dysfunction Syndrome, Temporomandibular Joint Pain, Range Of Motion, Yoga, Quality Of Life",Not Mentioned,Not Mentioned,"Scale (Npds), Disability",6 Weeks,Primary Endpoint
152,NCT04982601,"Temporomandibular Disorders, Myofascial Pain Dysfunction Syndrome, Temporomandibular Joint Pain, Range Of Motion, Yoga, Quality Of Life",Not Mentioned,Not Mentioned,Neck,6 Weeks,Primary Endpoint
153,NCT04982601,"Temporomandibular Disorders, Myofascial Pain Dysfunction Syndrome, Temporomandibular Joint Pain, Range Of Motion, Yoga, Quality Of Life",Not Mentioned,Not Mentioned,Quality Index (Puqi),6 Weeks,Secondary Endpoint
154,NCT04982601,"Temporomandibular Disorders, Myofascial Pain Dysfunction Syndrome, Temporomandibular Joint Pain, Range Of Motion, Yoga, Quality Of Life",Not Mentioned,Not Mentioned,Not Mentioned,6 Weeks,Secondary Endpoint
155,NCT04982601,"Temporomandibular Disorders, Myofascial Pain Dysfunction Syndrome, Temporomandibular Joint Pain, Range Of Motion, Yoga, Quality Of Life",Not Mentioned,Not Mentioned,Not Mentioned,36 (Sf36),Secondary Endpoint
156,NCT04982523,Post Traumatic Stress Disorder,Change Of Post-Traumatic Stress Symptoms,Not Mentioned,Not Mentioned,"Baseline, 4 Weeks, 8Weeks",Primary Endpoint
157,NCT04982523,Post Traumatic Stress Disorder,Change Of Depression,Not Mentioned,Not Mentioned,"Baseline, 4 Weeks, 8Weeks",Secondary Endpoint
158,NCT04982523,Post Traumatic Stress Disorder,Not Mentioned,Not Mentioned,Not Mentioned,"Baseline, 4 Weeks, 8Weeks",Secondary Endpoint
159,NCT04982523,Post Traumatic Stress Disorder,Not Mentioned,Not Mentioned,Not Mentioned,"Baseline, 4 Weeks, 8Weeks",Secondary Endpoint
160,NCT04982484,"Ophthalmopathy, Wet Macular Degeneration",Reading Speed,Not Mentioned,Not Mentioned,Day 0,Primary Endpoint
161,NCT04982484,"Ophthalmopathy, Wet Macular Degeneration",Reading Speed M3,Not Mentioned,Not Mentioned,Month 3,Primary Endpoint
162,NCT04982484,"Ophthalmopathy, Wet Macular Degeneration",Not Mentioned,"Etdrs Chart, Visual Acuity",Not Mentioned,Day 0,Secondary Endpoint
163,NCT04982484,"Ophthalmopathy, Wet Macular Degeneration",Not Mentioned,"Etdrs Chartm3, Visual Acuity",Not Mentioned,Month 3,Secondary Endpoint
164,NCT04982484,"Ophthalmopathy, Wet Macular Degeneration",Not Mentioned,Not Mentioned,Not Mentioned,Day 0,Secondary Endpoint
165,NCT04982341,Hypoxemic Respiratory Failure,Number Of Patients,Not Mentioned,Intubation,"Through Study Completion, An Average Of 28 Days",Primary Endpoint
166,NCT04982341,Hypoxemic Respiratory Failure,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
167,NCT04982263,Covid19,Not Mentioned,"Correlation, Results Of Laboratory Test, Disease Severity","Correlation, Results Of Laboratory Test, Disease Severity",Baseline Results Of Coagulation Profile And Baseline Disease Severity Assessment,Primary Endpoint
168,NCT04982263,Covid19,Not Mentioned,"Coagulation Profile, Measured Inflammatory Markers","Coagulation Profile, Measured Inflammatory Markers",Baseline Measurement Of Inflammatory Markers,Secondary Endpoint
169,NCT04982159,Invasive Fusariosis,Not Mentioned,Clinical Evolution,Not Mentioned,6 Weeks After Diagnosis,Primary Endpoint
170,NCT04982159,Invasive Fusariosis,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
171,NCT04982055,Critical Illness,Not Mentioned,Not Mentioned,Anti-Xa Activity,Peak Anti-Xa Activity Obtained 4 Hours After Start Of Low Molecular Weight Heparin Administration,Primary Endpoint
172,NCT04982055,Critical Illness,24H),Not Mentioned,Not Mentioned,0-24 Hours,Secondary Endpoint
173,NCT04981652,"Dairy Products, Muscle Protein Synthesis, Aging, Physical Activity",Not Mentioned,Not Mentioned,Not Mentioned,"Assessed At Baseline (Day 0-3), Intervention Diet (4-7) And Intervention Diet + Activity (Day 8-10)",Primary Endpoint
174,NCT04981652,"Dairy Products, Muscle Protein Synthesis, Aging, Physical Activity",Not Mentioned,Not Mentioned,Not Mentioned,"Assessed At Baseline (Day 0-3), Intervention Diet (4-7) And Intervention Diet + Activity (Day 8-10)",Secondary Endpoint
175,NCT04981561,Major Depressive Disorder,Not Mentioned,Not Mentioned,Treatment Emergent Adverse Events,28 Days,Primary Endpoint
176,NCT04981561,Major Depressive Disorder,Not Mentioned,Not Mentioned,Not Mentioned,24 Hours,Secondary Endpoint
177,NCT04981561,Major Depressive Disorder,Not Mentioned,Not Mentioned,Not Mentioned,24 Hours,Secondary Endpoint
178,NCT04981561,Major Depressive Disorder,Not Mentioned,"Plasma Concentration, Curve","Plasma Concentration, Curve",72 Hours,Secondary Endpoint
179,NCT04981483,Placenta Accreta,Not Mentioned,"Rate, Conserving Woman'S Uterus","Rate, Conserving Woman'S Uterus",Intraoperative,Primary Endpoint
180,NCT04981483,Placenta Accreta,Number Of Units Of Packed,Not Mentioned,"Blood Cells , Fresh Frozen Plasma Transfused ,Postoperative Haemoglobin",Till 48 Hours Postpartum,Secondary Endpoint
181,NCT04981483,Placenta Accreta,Cesarean Hysterectomy Needed,Rate,Not Mentioned,Intraoperative And 48 Hours Postpartum,Secondary Endpoint
182,NCT04981483,Placenta Accreta,Not Mentioned,Not Mentioned,Puerperal Sepsis,Till 6 Weeks Postpartum,Secondary Endpoint
183,NCT04981379,Covid19,Not Mentioned,Not Mentioned,Not Mentioned,Fifth Day After Examination,Secondary Endpoint
184,NCT04981379,Covid19,Not Mentioned,Not Mentioned,Not Mentioned,Tenth Day After Examination,Secondary Endpoint
185,NCT04981379,Covid19,Not Mentioned,Not Mentioned,Not Mentioned,Tenth Day After Examination,Secondary Endpoint
186,NCT04981379,Covid19,Not Mentioned,Not Mentioned,Not Mentioned,Tenth Day After Examination,Secondary Endpoint
187,NCT04981379,Covid19,Not Mentioned,Not Mentioned,Not Mentioned,Thirtieth Day After Examination,Secondary Endpoint
188,NCT04981379,Covid19,Not Mentioned,Not Mentioned,Not Mentioned,During The Study,Secondary Endpoint
189,NCT04981379,Covid19,Not Mentioned,Not Mentioned,Not Mentioned,During The Study,Secondary Endpoint
190,NCT04981379,Covid19,Requirement Of Mechanical Ventilation,Not Mentioned,Not Mentioned,During The Study,Secondary Endpoint
191,NCT04981379,Covid19,Not Mentioned,Not Mentioned,Not Mentioned,During The Study,Secondary Endpoint
192,NCT04981379,Covid19,Not Mentioned,Not Mentioned,Time To Improvement Of Symptoms After The Initiation Of Study Drugs,During The Study,Secondary Endpoint
193,NCT04981249,"Covid-19, Chronic Disease",Not Mentioned,Not Mentioned,Not Mentioned,From 27-February-2020 To 15-June-2020,Primary Endpoint
194,NCT04981249,"Covid-19, Chronic Disease",Covid-19 Mortality,Not Mentioned,Not Mentioned,From 27-February-2020 To 15-June-2020,Primary Endpoint
195,NCT04981249,"Covid-19, Chronic Disease",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
196,NCT04981197,Heart Failure,Not Mentioned,Not Mentioned,Changes,"Baseline, 4 Week, 8 Week, 12 Week",Primary Endpoint
197,NCT04981197,Heart Failure,Not Mentioned,Not Mentioned,Changes,"Baseline, 4 Week, 8 Week, 12 Week",Primary Endpoint
198,NCT04981197,Heart Failure,Not Mentioned,Not Mentioned,"Quality Index Scores, Changes","Baseline, 4 Week, 8 Week, 12 Week",Secondary Endpoint
199,NCT04981197,Heart Failure,Not Mentioned,Not Mentioned,Changes,"Baseline, 4 Week, 8 Week, 12 Week",Secondary Endpoint
200,NCT04981197,Heart Failure,Not Mentioned,Not Mentioned,Not Mentioned,"Baseline, 4 Week, 8 Week, 12 Week",Secondary Endpoint
201,NCT04981106,Exercise,Not Mentioned,Not Mentioned,Not Mentioned,First Measurement Two Weeks After Surgery (Intervetion 58.2; Control 54.1),Primary Endpoint
202,NCT04981106,Exercise,Not Mentioned,Not Mentioned,Not Mentioned,First Measurement Two Weeks After Surgery (Intervetion 89.3; Control 88.1),Primary Endpoint
203,NCT04981106,Exercise,Not Mentioned,Not Mentioned,Not Mentioned,First Measurement Two Weeks After Surgery (Intervetion 21.6; Control 22.1),Primary Endpoint
204,NCT04981106,Exercise,Not Mentioned,Not Mentioned,Not Mentioned,Second Measurement Six Weeks After Surgery (Intervetion 36.9; Control 42.9),Secondary Endpoint
205,NCT04981106,Exercise,Not Mentioned,Not Mentioned,Not Mentioned,Second Measurement Six Weeks After Surgery (Intervetion 29; Control 70.5),Secondary Endpoint
206,NCT04981106,Exercise,Not Mentioned,Not Mentioned,Not Mentioned,Second Measurement Six Weeks After Surgery (Intervetion 6.9; Control 13.2),Secondary Endpoint
207,NCT04981080,"Detrusor Underactivity, Bladder Outlet Obstruction",Detrusor Underactivity,Not Mentioned,Not Mentioned,February 2005 And December 2020,Primary Endpoint
208,NCT04981080,"Detrusor Underactivity, Bladder Outlet Obstruction",Bladder Outlet Obstruction,Not Mentioned,Not Mentioned,February 2005 And December 2020,Primary Endpoint
209,NCT04981080,"Detrusor Underactivity, Bladder Outlet Obstruction",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
210,NCT04981054,"Bladder Oversensitivity, Detrusor, Overactive",Bladder Oversensitivity,Not Mentioned,Not Mentioned,November 2010 And October 2020,Primary Endpoint
211,NCT04981054,"Bladder Oversensitivity, Detrusor, Overactive",Not Mentioned,Not Mentioned,Not Mentioned,November 2010 And October 2020,Primary Endpoint
212,NCT04981054,"Bladder Oversensitivity, Detrusor, Overactive",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
213,NCT04981015,Bladder Oversensitivity,Not Mentioned,"Correlation, Parameters","Correlation, Parameters",July 2009 To December 2020,Primary Endpoint
214,NCT04981015,Bladder Oversensitivity,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
215,NCT04980989,"Breast Cancer, Early-Onset",Not Mentioned,Not Mentioned,"Patient Preference, Follow-Up Modality",At 12 Months During Follow-Up Of Early Breast Cancer,Primary Endpoint
216,NCT04980989,"Breast Cancer, Early-Onset",Not Mentioned,Not Mentioned,Quality Of Life During Follow-Up Modality,"At Baseline, 6 Months And 12 Months",Secondary Endpoint
217,NCT04980989,"Breast Cancer, Early-Onset",Not Mentioned,Not Mentioned,Patient Satisfaction,At 6 Months And 12 Months,Secondary Endpoint
218,NCT04980989,"Breast Cancer, Early-Onset",Not Mentioned,Not Mentioned,Not Mentioned,"At Baseline, 6 Months And 12 Months",Secondary Endpoint
219,NCT04980989,"Breast Cancer, Early-Onset",Not Mentioned,Not Mentioned,Other Healthcare Services,At 6 Months And 12 Months,Secondary Endpoint
220,NCT04980937,"Traumatic Injury, Peroneal Nerve Injury, Sport Injury",Successful Nerve Reconstruction,Not Mentioned,Not Mentioned,1 Year,Primary Endpoint
221,NCT04980937,"Traumatic Injury, Peroneal Nerve Injury, Sport Injury",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
222,NCT04980729,Pelvic Tumor,Acetabular Rotation Center Before,Not Mentioned,"Operation Group, Template-Guided Group","""Through Study Completion, An Average Of 2 Years""",Primary Endpoint
223,NCT04980729,Pelvic Tumor,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
224,NCT04980586,"Obstructive Sleep Apnea, Breathing, Sleep-Disordered, Muscle Weakness, Muscle Disorder, Face, Swallowing Disorder",Not Mentioned,Not Mentioned,Cheeks Appearance,Immediately After The Evaluation,Primary Endpoint
225,NCT04980586,"Obstructive Sleep Apnea, Breathing, Sleep-Disordered, Muscle Weakness, Muscle Disorder, Face, Swallowing Disorder",Evaluation Of Specific Orofacial Muscles,Not Mentioned,Not Mentioned,Immediately After The Evaluation,Secondary Endpoint
226,NCT04980586,"Obstructive Sleep Apnea, Breathing, Sleep-Disordered, Muscle Weakness, Muscle Disorder, Face, Swallowing Disorder",Not Mentioned,Not Mentioned,Not Mentioned,Immediately After The Evaluation,Secondary Endpoint
227,NCT04980508,"Erectile Dysfunction Due To Diseases Classified Elsewhere, Covid19",Corpus Cavernosum Electromyography Amplitudes,Not Mentioned,Not Mentioned,1 Hour,Primary Endpoint
228,NCT04980508,"Erectile Dysfunction Due To Diseases Classified Elsewhere, Covid19",Corpus Cavernosum Electromyography Relaxation Degree,Not Mentioned,Not Mentioned,1 Hour,Primary Endpoint
229,NCT04980508,"Erectile Dysfunction Due To Diseases Classified Elsewhere, Covid19",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
230,NCT04980274,Critically Ill Patients,Icu Stay,Improvement,Not Mentioned,48 Hours,Primary Endpoint
231,NCT04980274,Critically Ill Patients,28 Day Mortality,Not Mentioned,Not Mentioned,28 Days,Secondary Endpoint
232,NCT04980274,Critically Ill Patients,Not Mentioned,Not Mentioned,Time Without Mechanical Ventilation,28 Days,Secondary Endpoint
233,NCT04980274,Critically Ill Patients,Not Mentioned,Not Mentioned,Time Without Vasopressor,28 Days,Secondary Endpoint
234,NCT04980209,Femoroacetabular Impingement,Vas Scale,Not Mentioned,Not Mentioned,1 Year After Operation,Primary Endpoint
235,NCT04980209,Femoroacetabular Impingement,Mhhs Scale,Not Mentioned,Not Mentioned,1 Year After Operation,Primary Endpoint
236,NCT04980209,Femoroacetabular Impingement,Hip Ct,Not Mentioned,Not Mentioned,1 Day After Operation,Primary Endpoint
237,NCT04980209,Femoroacetabular Impingement,Not Mentioned,Not Mentioned,Not Mentioned,1 Day After Operation,Primary Endpoint
238,NCT04980209,Femoroacetabular Impingement,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
239,NCT04980196,Urogenital Prolapse,Urological Outcome Following Surgery In Women,Not Mentioned,"Tract Dysfunction, Pelvic Organ Prolapse",3Months,Primary Endpoint
240,NCT04980196,Urogenital Prolapse,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
241,NCT04980131,Vertebral Fracture,Time Before Reaching,Not Mentioned,"Number Of Fluoroscopy Before Reaching, Position",Twenty Months,Primary Endpoint
242,NCT04980131,Vertebral Fracture,Vas Scores After Surgery,Not Mentioned,Not Mentioned,Twenty-Two Months,Primary Endpoint
243,NCT04980131,Vertebral Fracture,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
244,NCT04980118,"Breast Cancer, Body Weight Changes, Weight Loss, Nutrition Related Cancer",Physical Activity Program,Not Mentioned,"To Evaluate, Nutritional Intervention",Six Months,Primary Endpoint
245,NCT04980118,"Breast Cancer, Body Weight Changes, Weight Loss, Nutrition Related Cancer",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
246,NCT04980040,Type 2 Diabetes Mellitus,Percentage Of Participants,Not Mentioned,Serious Adverse Events (Saes),From First Dose Of Study Drug Up To 30 Days Post Last Dose Of Study Drug (Up To 79.77 Weeks),Primary Endpoint
247,NCT04980040,Type 2 Diabetes Mellitus,Percentage Of Participants,Not Mentioned,Serious Adverse Drug Reactions (Adrs),From First Dose Of Study Drug Up To 30 Days Post Last Dose Of Study Drug (Up To 79.77 Weeks),Primary Endpoint
248,NCT04980040,Type 2 Diabetes Mellitus,Percentage Of Participants,Not Mentioned,Not Mentioned,From First Dose Of Study Drug Up To 30 Days Post Last Dose Of Study Drug (Up To 79.77 Weeks),Primary Endpoint
249,NCT04980040,Type 2 Diabetes Mellitus,Percentage Of Participants,Not Mentioned,Unexpected Adverse Drug Reactions (Adrs),From First Dose Of Study Drug Up To 30 Days Post Last Dose Of Study Drug (Up To 79.77 Weeks),Primary Endpoint
250,NCT04980040,Type 2 Diabetes Mellitus,Haemoglobin (Hba1C) Levels,Not Mentioned,Not Mentioned,"Baseline (Before Administration Of Alogliptin), 13 Weeks (±2 Weeks) And 26 Weeks (±2 Weeks) After Administration",Secondary Endpoint
251,NCT04980040,Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,Not Mentioned,"Baseline (Before Administration Of Alogliptin), 13 Weeks (±2 Weeks) And 26 Weeks (±2 Weeks) After Administration",Secondary Endpoint
252,NCT04980040,Type 2 Diabetes Mellitus,Percentage Of Participants,Not Mentioned,Hba1C < 7.00%,"Baseline (Before Administration Of Alogliptin), 13 Weeks (±2 Weeks) And 26 Weeks (±2 Weeks) After Administration",Secondary Endpoint
253,NCT04980040,Type 2 Diabetes Mellitus,Percentage Of Participants,Overall,Not Mentioned,Up To Week 26,Secondary Endpoint
254,NCT04980014,Type 2 Diabetes Mellitus,Percentage Of Participants,Not Mentioned,"Serious Adverse Drug Reactions (Sadrs), Serious Adverse Events (Saes)",First Dose Of Surveillance Drug Treatment To Within 30 Days After The End Of The Treatment (Up To 153 Weeks),Primary Endpoint
255,NCT04980014,Type 2 Diabetes Mellitus,Percentage Of Participants,Not Mentioned,Adverse Drug Reactions (Adrs) Not Mentioned In Precautions,First Dose Of Surveillance Drug Treatment To Within 30 Days After The End Of The Treatment (Up To 153 Weeks),Primary Endpoint
256,NCT04980014,Type 2 Diabetes Mellitus,Percentage Of Participants,Not Mentioned,Not Mentioned,Week 13,Primary Endpoint
257,NCT04980014,Type 2 Diabetes Mellitus,Percentage Of Participants,Not Mentioned,Not Mentioned,Week 26,Primary Endpoint
258,NCT04980014,Type 2 Diabetes Mellitus,Percentage Of Participants,Not Mentioned,Not Mentioned,Week 39,Primary Endpoint
259,NCT04980014,Type 2 Diabetes Mellitus,Percentage Of Participants,Not Mentioned,Not Mentioned,Week 52,Primary Endpoint
260,NCT04980014,Type 2 Diabetes Mellitus,Percentage Of Participants,Not Mentioned,Not Mentioned,Week 153,Primary Endpoint
261,NCT04980014,Type 2 Diabetes Mellitus,Percentage Of Participants,Not Mentioned,Non-Serious Adrs,First Dose Of Surveillance Drug Treatment To Within 30 Days After The End Of The Treatment (Up To 153 Weeks),Primary Endpoint
262,NCT04980014,Type 2 Diabetes Mellitus,Percentage Of Participants,Not Mentioned,Abnormal Laboratory Findings Reported As Aes,First Dose Of Surveillance Drug Treatment To Within 30 Days After The End Of The Treatment (Up To 153 Weeks),Primary Endpoint
263,NCT04980014,Type 2 Diabetes Mellitus,Haemoglobin A1C (Hba1C) Levels,Baseline,Not Mentioned,"Baseline, Weeks 13 And 26",Secondary Endpoint
264,NCT04980014,Type 2 Diabetes Mellitus,Change,"Fasting Serum Glucose, Baseline","Fasting Serum Glucose, Baseline","Baseline, Weeks 13 And 26",Secondary Endpoint
265,NCT04980014,Type 2 Diabetes Mellitus,Change,"Total Cholesterol, Baseline","Total Cholesterol, Baseline","Baseline, Weeks 13 And 26",Secondary Endpoint
266,NCT04980014,Type 2 Diabetes Mellitus,Change,Baseline,Not Mentioned,"Baseline, Weeks 13 And 26",Secondary Endpoint
267,NCT04980014,Type 2 Diabetes Mellitus,Change,Baseline,Not Mentioned,"Baseline, Weeks 13 And 26",Secondary Endpoint
268,NCT04980014,Type 2 Diabetes Mellitus,Change,Baseline,Not Mentioned,"Baseline, Weeks 13 And 26",Secondary Endpoint
269,NCT04980014,Type 2 Diabetes Mellitus,Change,Baseline,Not Mentioned,"Baseline, Weeks 13 And 26",Secondary Endpoint
270,NCT04980014,Type 2 Diabetes Mellitus,Change,Baseline,Not Mentioned,"Baseline, Weeks 13 And 26",Secondary Endpoint
271,NCT04979936,"Acute Cholecystitis, Empyema, Gallbladder",Biliary Injury,Operative Time,Not Mentioned,At The Time Of Cholecysctomy,Primary Endpoint
272,NCT04979936,"Acute Cholecystitis, Empyema, Gallbladder",Not Mentioned,Not Mentioned,Postoperative Complications,30 Days After The Operation,Primary Endpoint
273,NCT04979936,"Acute Cholecystitis, Empyema, Gallbladder",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
274,NCT04979689,Erbs Palsy,Not Mentioned,Not Mentioned,Not Mentioned,12Th Weeks,Primary Endpoint
275,NCT04979689,Erbs Palsy,Not Mentioned,Not Mentioned,Not Mentioned,"12Th Weeks, 5Th Day",Secondary Endpoint
276,NCT04979481,Mental Health Wellness 1,Not Mentioned,Health,Not Mentioned,Up To 8 Months,Primary Endpoint
277,NCT04979481,Mental Health Wellness 1,Not Mentioned,Not Mentioned,Not Mentioned,Up To 8 Months,Primary Endpoint
278,NCT04979481,Mental Health Wellness 1,Not Mentioned,Not Mentioned,Not Mentioned,Up To 8 Months,Primary Endpoint
279,NCT04979481,Mental Health Wellness 1,Not Mentioned,Not Mentioned,Self-Esteem,Up To 8 Months,Primary Endpoint
280,NCT04979481,Mental Health Wellness 1,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
281,NCT04979364,"Chronic Pain, Opioid Misuse",Psychometric Properties,Not Mentioned,Pomi Scale,Once. At Inclusion (Test Phase),Primary Endpoint
282,NCT04979364,"Chronic Pain, Opioid Misuse",Psychometric Properties,Not Mentioned,Pomi Scale,Once. At 2 To 4 Weeks (Re-Test Phase),Primary Endpoint
283,NCT04979364,"Chronic Pain, Opioid Misuse",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
284,NCT04979208,"Coronavirus Disease 2019, Stroke, Acute Myocardial Infarction",Ami Patient,Not Mentioned,Not Mentioned,At Inclusion In The Cohort During The Acute Episode,Primary Endpoint
285,NCT04979208,"Coronavirus Disease 2019, Stroke, Acute Myocardial Infarction",Not Mentioned,Not Mentioned,Not Mentioned,At Inclusion In The Cohort During The Acute Episode,Primary Endpoint
286,NCT04979208,"Coronavirus Disease 2019, Stroke, Acute Myocardial Infarction",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
287,NCT04979195,Covid-19 Positive Patients With Acute Kidney Injury,Patient Survival,Not Mentioned,Not Mentioned,30 Days,Primary Endpoint
288,NCT04979195,Covid-19 Positive Patients With Acute Kidney Injury,Not Mentioned,Not Mentioned,Not Mentioned,30 Days,Primary Endpoint
289,NCT04979195,Covid-19 Positive Patients With Acute Kidney Injury,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
290,NCT04979091,"Covid19, Critical Illness",Covid-19 Patients,Not Mentioned,Not Mentioned,Day At Admission,Primary Endpoint
291,NCT04979091,"Covid19, Critical Illness",Sex Hormone,Not Mentioned,Not Mentioned,Day At Admission,Primary Endpoint
292,NCT04979091,"Covid19, Critical Illness",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
293,NCT04979026,Deep Venous Thrombosis,Change Of Peak Flow Velocity,Not Mentioned,Not Mentioned,"The Peak Flow Velocity Was Determined On The 1St, 3Rd, And 14Th Days After Surgery.",Primary Endpoint
294,NCT04979026,Deep Venous Thrombosis,Change Of Flow Volume,Not Mentioned,Not Mentioned,"The Flow Volume Was Determined On The 1St, 3Rd, And 14Th Days After Surgery.",Primary Endpoint
295,NCT04979026,Deep Venous Thrombosis,Number Of Participants,Not Mentioned,Not Mentioned,"Stasis Was Determined On The 1St, 3Rd, And 14Th Days After Surgery.",Primary Endpoint
296,NCT04979026,Deep Venous Thrombosis,Number Of Participants,Not Mentioned,Not Mentioned,"Deep Venous Thrombosis Was Determined On The 1St, 3Rd, And 14Th Days After Surgery.",Primary Endpoint
297,NCT04979026,Deep Venous Thrombosis,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
298,NCT04979013,"Smoking, Smoking Cessation, Tobacco Use",Not Mentioned,Not Mentioned,Leukotriene E4 (Lte4),14 Days,Primary Endpoint
299,NCT04979013,"Smoking, Smoking Cessation, Tobacco Use",Not Mentioned,Not Mentioned,Not Mentioned,7 Days,Secondary Endpoint
300,NCT04979013,"Smoking, Smoking Cessation, Tobacco Use",Not Mentioned,Not Mentioned,Not Mentioned,14 Days,Secondary Endpoint
301,NCT04979013,"Smoking, Smoking Cessation, Tobacco Use",Not Mentioned,"Urine, Nicotine Equivalents And Cema","Urine, Nicotine Equivalents And Cema",14 Days,Secondary Endpoint
302,NCT04979013,"Smoking, Smoking Cessation, Tobacco Use",Not Mentioned,"Urine, Tsnas",Not Mentioned,14 Days,Secondary Endpoint
303,NCT04979013,"Smoking, Smoking Cessation, Tobacco Use",Not Mentioned,Not Mentioned,Not Mentioned,14 Days,Secondary Endpoint
304,NCT04979013,"Smoking, Smoking Cessation, Tobacco Use",Not Mentioned,Cotinine,Not Mentioned,14 Days,Secondary Endpoint
305,NCT04979013,"Smoking, Smoking Cessation, Tobacco Use",Not Mentioned,Not Mentioned,Feno,14 Days,Secondary Endpoint
306,NCT04979013,"Smoking, Smoking Cessation, Tobacco Use",Not Mentioned,Not Mentioned,Not Mentioned,14 Days,Secondary Endpoint
307,NCT04979013,"Smoking, Smoking Cessation, Tobacco Use",Stt),Not Mentioned,Not Mentioned,14 Days,Secondary Endpoint
308,NCT04979013,"Smoking, Smoking Cessation, Tobacco Use",Not Mentioned,T-,Not Mentioned,14 Days,Secondary Endpoint
309,NCT04979013,"Smoking, Smoking Cessation, Tobacco Use",Not Mentioned,Not Mentioned,Changes,14 Days,Secondary Endpoint
310,NCT04978974,"Chronic Conditions, Multiple",Stress Management Program,Not Mentioned,Not Mentioned,10Th Session (One Month And One Week From First Assessment),Primary Endpoint
311,NCT04978974,"Chronic Conditions, Multiple",Stress Management Program,Health-Related Quality,Not Mentioned,10Th Session (One Month And One Week From First Assessment),Primary Endpoint
312,NCT04978974,"Chronic Conditions, Multiple",Stress Management Program,Not Mentioned,Not Mentioned,10Th Session (One Month And One Week From First Assessment),Primary Endpoint
313,NCT04978974,"Chronic Conditions, Multiple",Stress Management Program,Baseline,Not Mentioned,Base Line Were Used In 5Th (Two Weeks And 3 Days) And 10Th Session (One Month And One Week From First Assessment),Secondary Endpoint
314,NCT04978961,Chronic Pain,Not Mentioned,Not Mentioned,Self-Reported Physical Disability,Booster (12 Weeks From Baseline),Primary Endpoint
315,NCT04978961,Chronic Pain,Not Mentioned,Not Mentioned,Self-Reported Physical Disability,6-Month Follow-Up,Primary Endpoint
316,NCT04978961,Chronic Pain,Ratings),Not Mentioned,"Intervention, Satisfaction, Study (Attrition",6-Month Follow-Up,Primary Endpoint
317,NCT04978961,Chronic Pain,Not Mentioned,Not Mentioned,Fact Intervention,6-Month Follow-Up,Primary Endpoint
318,NCT04978961,Chronic Pain,Not Mentioned,Not Mentioned,Not Mentioned,Booster (12 Weeks From Baseline),Secondary Endpoint
319,NCT04978961,Chronic Pain,Not Mentioned,Not Mentioned,Not Mentioned,6-Month Follow-Up,Secondary Endpoint
320,NCT04978961,Chronic Pain,Not Mentioned,Not Mentioned,Not Mentioned,Booster (12 Weeks From Baseline),Secondary Endpoint
321,NCT04978961,Chronic Pain,Not Mentioned,Not Mentioned,Not Mentioned,6-Month Follow-Up,Secondary Endpoint
322,NCT04978883,Sjogren'S Syndrome,Not Mentioned,Not Mentioned,Pss-Ild,6 Months From Baseline,Primary Endpoint
323,NCT04978883,Sjogren'S Syndrome,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
324,NCT04978805,Cancer,Not Mentioned,Not Mentioned,Not Mentioned,1.Week,Primary Endpoint
325,NCT04978805,Cancer,Not Mentioned,Not Mentioned,Not Mentioned,4.Week,Primary Endpoint
326,NCT04978805,Cancer,Not Mentioned,Not Mentioned,Not Mentioned,8.Week,Primary Endpoint
327,NCT04978805,Cancer,Not Mentioned,Not Mentioned,Not Mentioned,1.Week,Primary Endpoint
328,NCT04978805,Cancer,Not Mentioned,Not Mentioned,Not Mentioned,4.Week,Primary Endpoint
329,NCT04978805,Cancer,Not Mentioned,Not Mentioned,Not Mentioned,8.Week,Primary Endpoint
330,NCT04978805,Cancer,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
331,NCT04978714,"Urodynamic Stress Incontinence, Detrusor Overactivity",Not Mentioned,Not Mentioned,Not Mentioned,November 2010 And October 2020,Primary Endpoint
332,NCT04978714,"Urodynamic Stress Incontinence, Detrusor Overactivity",Not Mentioned,Not Mentioned,Not Mentioned,November 2010 And October 2020,Primary Endpoint
333,NCT04978714,"Urodynamic Stress Incontinence, Detrusor Overactivity",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
334,NCT04978688,Healthy,Not Mentioned,"Pk, Hour 24 (Auc0-24), : Area Under, Time","Pk, Hour 24 (Auc0-24), : Area Under, Time",Predose And Up To 24 Hours At Weeks 3 And 6,Primary Endpoint
335,NCT04978688,Healthy,Not Mentioned,Not Mentioned,"Maximum Concentration, Pk",Predose And Up To 24 Hours At Weeks 3 And 6,Primary Endpoint
336,NCT04978688,Healthy,Not Mentioned,Not Mentioned,"Pk, Time To Maximum Concentration",Predose And Up To 24 Hours At Weeks 3 And 6,Primary Endpoint
337,NCT04978688,Healthy,Fsh),Baseline,Not Mentioned,Week 6,Secondary Endpoint
338,NCT04978688,Healthy,Change,Baseline,Not Mentioned,Week 6,Secondary Endpoint
339,NCT04978688,Healthy,Change,Baseline,Not Mentioned,Week 6,Secondary Endpoint
340,NCT04978688,Healthy,Change,Baseline,Not Mentioned,Week 6,Secondary Endpoint
341,NCT04978688,Healthy,Change,Baseline,Not Mentioned,Week 6,Secondary Endpoint
342,NCT04978688,Healthy,Not Mentioned,Not Mentioned,Treatment-Emergent Adverse Events,8 Weeks,Secondary Endpoint
343,NCT04978688,Healthy,Hot Flush,Not Mentioned,Not Mentioned,8 Weeks,Secondary Endpoint
344,NCT04978545,"Periapical Periodontitis, Polymerase Chain Reaction, Intracanal Medicament, Enterococcus Faecalis Infection",Sanger Sequencing,Not Mentioned,Rrna Genes,Change From Baseline To Postoperative 7 Days,Primary Endpoint
345,NCT04978545,"Periapical Periodontitis, Polymerase Chain Reaction, Intracanal Medicament, Enterococcus Faecalis Infection",S3) Taken From Teeth,Not Mentioned,Total Bacteria,Change From Baseline To Postoperative 7 Days,Primary Endpoint
346,NCT04978545,"Periapical Periodontitis, Polymerase Chain Reaction, Intracanal Medicament, Enterococcus Faecalis Infection",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
347,NCT04978532,"Procedural Pain, Pain, Acute",Children),Not Mentioned,Not Mentioned,Before Venipuncture Procedure And After Venipuncture Procedure (Immediately After The Injector Was Removed),Primary Endpoint
348,NCT04978532,"Procedural Pain, Pain, Acute",Change Of Pain From Before Venipuncture,Not Mentioned,Not Mentioned,Before Venipuncture Procedure And After Venipuncture Procedure (Immediately After The Injector Was Removed),Primary Endpoint
349,NCT04978532,"Procedural Pain, Pain, Acute",Not Mentioned,Not Mentioned,Not Mentioned,"Before Venipuncture Procedure, During Venipuncture Procedure (When Needle Insertion And The First Blood Was Seen In Injector, Until Needle Removed), And After Venipuncture Procedure (Immediately After The Injector Was Removed)",Secondary Endpoint
350,NCT04978532,"Procedural Pain, Pain, Acute",Not Mentioned,Not Mentioned,Not Mentioned,"Before Venipuncture Procedure, During Venipuncture Procedure (When Needle Insertion And The First Blood Was Seen In Injector, Until Needle Removed), And After Venipuncture Procedure (Immediately After The Injector Was Removed)",Secondary Endpoint
351,NCT04978441,"Significant Correlation Between Baseline Personality Characteristics, Changing Emotions Throughout The Day, And Glycemic Levels In Patients With T1Dm",Personality Characteristics,"Baseline, Correlation, T1Dm, Glycemic Levels, Patients","Baseline, Correlation, T1Dm, Glycemic Levels, Patients","Through Study Completion, An Average Of 1 Year",Primary Endpoint
352,NCT04978441,"Significant Correlation Between Baseline Personality Characteristics, Changing Emotions Throughout The Day, And Glycemic Levels In Patients With T1Dm",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
353,NCT04978402,"Interchromosomal Breakpoint, Infertility",Estimate The It Carrier'S Reproductive,Not Mentioned,Not Mentioned,Day 1,Primary Endpoint
354,NCT04978402,"Interchromosomal Breakpoint, Infertility",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
355,NCT04978233,Covid-19,Covid-19,Not Mentioned,Not Mentioned,From Day 1 To Day 14,Primary Endpoint
356,NCT04978233,Covid-19,Covid-19,Not Mentioned,Not Mentioned,From Day 1 To Day 14,Primary Endpoint
357,NCT04978233,Covid-19,Healthcare Team,Not Mentioned,Not Mentioned,From Day 1 To Day 14,Secondary Endpoint
358,NCT04978233,Covid-19,Change In Symptoms,Not Mentioned,Not Mentioned,From Day 1 To Day 14,Secondary Endpoint
359,NCT04978233,Covid-19,Not Mentioned,Not Mentioned,"Patient Satisfaction, Scheduled Teleconsultations",From Day 1 To Day 14,Secondary Endpoint
360,NCT04978233,Covid-19,Change,Not Mentioned,Not Mentioned,From Day 1 To Day 14,Secondary Endpoint
361,NCT04978233,Covid-19,Change,Not Mentioned,Not Mentioned,From Day 1 To Day 14,Secondary Endpoint
362,NCT04978233,Covid-19,Change,Not Mentioned,Not Mentioned,From Day 1 To Day 14,Secondary Endpoint
363,NCT04978233,Covid-19,Change,Not Mentioned,Not Mentioned,From Day 1 To Day 14,Secondary Endpoint
364,NCT04978233,Covid-19,Change,Not Mentioned,Blood Pressure,From Day 1 To Day 14,Secondary Endpoint
365,NCT04978220,"Depression Unipolar, Insomnia",Not Mentioned,Not Mentioned,Not Mentioned,1 Year,Primary Endpoint
366,NCT04978220,"Depression Unipolar, Insomnia",Not Mentioned,Not Mentioned,Not Mentioned,1 Year,Secondary Endpoint
367,NCT04978155,Arterio-Venous Fistula,Not Mentioned,Time,Not Mentioned,6 Weeks,Primary Endpoint
368,NCT04978155,Arterio-Venous Fistula,Not Mentioned,"Time, Avf That Is Finally Placed, Rate Of Planning Change, Surgical Project","Time, Avf That Is Finally Placed, Rate Of Planning Change, Surgical Project",During The Surgery,Secondary Endpoint
369,NCT04978155,Arterio-Venous Fistula,Not Mentioned,Not Mentioned,Accesses,12 Months,Secondary Endpoint
370,NCT04977921,Educational Problems,Not Mentioned,Not Mentioned,Improve Student'S Performance Per Clinical,13 Lab Session-13 Weeks,Primary Endpoint
371,NCT04977921,Educational Problems,Evaluate Effectiveness Of Teaching Pedagogy,Not Mentioned,Not Mentioned,Week 14,Primary Endpoint
372,NCT04977921,Educational Problems,Assess Students' Perception Of Usability,Not Mentioned,Learning Of Elsevier Clinical Skill,Up To 15 Weeks,Secondary Endpoint
373,NCT04977713,"Labor Pain, Hydrotherapy, Acupressure, Postpartum Period",Reduce Labor Pain,Not Mentioned,Not Mentioned,Evaluation Was Done Until Delivery (On Average Between 8-12 Hours),Primary Endpoint
374,NCT04977713,"Labor Pain, Hydrotherapy, Acupressure, Postpartum Period",Not Mentioned,Not Mentioned,Not Mentioned,2 Hours After Birth,Primary Endpoint
375,NCT04977713,"Labor Pain, Hydrotherapy, Acupressure, Postpartum Period",Vasp),Not Mentioned,Not Mentioned,Evaluation Was Done Until Delivery (On Average Between 8-12 Hours),Primary Endpoint
376,NCT04977713,"Labor Pain, Hydrotherapy, Acupressure, Postpartum Period",Ppcq),Not Mentioned,Not Mentioned,2 Hours After Birth,Primary Endpoint
377,NCT04977713,"Labor Pain, Hydrotherapy, Acupressure, Postpartum Period",Not Mentioned,Not Mentioned,Evalution Labour Pain,Evaluation Was Done Until Delivery (On Average Between 8-12 Hours),Primary Endpoint
378,NCT04977713,"Labor Pain, Hydrotherapy, Acupressure, Postpartum Period",Not Mentioned,Not Mentioned,Not Mentioned,2 Hours After Birth,Primary Endpoint
379,NCT04977713,"Labor Pain, Hydrotherapy, Acupressure, Postpartum Period",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
380,NCT04977687,"Machine Learning, Acute Kidney Injury, Renal Replacement Therapy, Prediction Models",Patients Required Renal Replacement Therapy,Not Mentioned,Not Mentioned,14 Days,Primary Endpoint
381,NCT04977687,"Machine Learning, Acute Kidney Injury, Renal Replacement Therapy, Prediction Models",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
382,NCT04977661,Nonalcoholic Steatohepatitis (Nash),Not Mentioned,Not Mentioned,Not Mentioned,3 Months,Primary Endpoint
383,NCT04977661,Nonalcoholic Steatohepatitis (Nash),Not Mentioned,Not Mentioned,Not Mentioned,3 Months,Secondary Endpoint
384,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Not Mentioned,Not Mentioned,Not Mentioned,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
385,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Not Mentioned,Not Mentioned,Tumor Location,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
386,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Number Of Lesions,Not Mentioned,Not Mentioned,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
387,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Not Mentioned,Not Mentioned,Not Mentioned,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
388,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Not Mentioned,Not Mentioned,Not Mentioned,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
389,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Not Mentioned,Not Mentioned,Not Mentioned,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
390,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Not Mentioned,Not Mentioned,Not Mentioned,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
391,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Not Mentioned,Not Mentioned,Pancreatic Duct/Bile Duct Dilatation,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
392,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Not Mentioned,Not Mentioned,Extrapancreatic Tissue Invasion,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
393,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Hepatic Metastasis,Not Mentioned,Not Mentioned,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
394,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Not Mentioned,Not Mentioned,Not Mentioned,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
395,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Ct Value Of Pancreas Plain Scan,Not Mentioned,Not Mentioned,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
396,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Plain Scan,Not Mentioned,Not Mentioned,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
397,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Ct Value Of Pancreas Artery Phase,Not Mentioned,Not Mentioned,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
398,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Ct Value,Not Mentioned,Lesion Artery Phase,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
399,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Ct Value Of Pancreas Portal Phase,Not Mentioned,Not Mentioned,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
400,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Ct Value,Not Mentioned,Not Mentioned,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
401,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
402,NCT04977557,Dry Beriberi,Change,Not Mentioned,Overall Neuropathy Limitation Scale (Onls) Score,"Before Treatment With Thiamine (Baseline ) And After 1 Week, 6Week, 12 Week Of Treatment",Primary Endpoint
403,NCT04977557,Dry Beriberi,Change In Leg Swelling,Not Mentioned,Not Mentioned,"Before Treatment With Thiamine (Baseline ) And After 1 Week, 6Week, 12 Week Of Treatment",Secondary Endpoint
404,NCT04977557,Dry Beriberi,Change In Muscle Power,Not Mentioned,Not Mentioned,"Before Treatment With Thiamine (Baseline ) And After 1 Week, 6Week, 12 Week Of Treatment",Secondary Endpoint
405,NCT04977557,Dry Beriberi,Change In Muscle Cramp,Not Mentioned,Not Mentioned,"Before Treatment With Thiamine (Baseline ) And After 1 Week, 6Week, 12 Week Of Treatment",Secondary Endpoint
406,NCT04977557,Dry Beriberi,Deep Tendon Reflexes,Not Mentioned,Not Mentioned,"Before Treatment With Thiamine (Baseline ) And After 1 Week, 6Week, 12 Week Of Treatment",Secondary Endpoint
407,NCT04977557,Dry Beriberi,Change In Squat Test,Not Mentioned,Not Mentioned,"Before Treatment With Thiamine (Baseline ) And After 1 Week, 6Week, 12 Week Of Treatment",Secondary Endpoint
408,NCT04977557,Dry Beriberi,Change In Pain Sensation,Not Mentioned,Not Mentioned,"Before Treatment With Thiamine (Baseline ) And After 1 Week, 6Week, 12 Week Of Treatment",Secondary Endpoint
409,NCT04977557,Dry Beriberi,Change In Position Sensation,Not Mentioned,Not Mentioned,"Before Treatment With Thiamine (Baseline ) And After 1 Week, 6Week, 12 Week Of Treatment",Secondary Endpoint
410,NCT04977557,Dry Beriberi,Change In Vibration Sensation,Not Mentioned,Not Mentioned,"Before Treatment With Thiamine (Baseline ) And After 1 Week, 6Week, 12 Week Of Treatment",Secondary Endpoint
411,NCT04977557,Dry Beriberi,Change In Touch Sensation,Not Mentioned,Not Mentioned,"Before Treatment With Thiamine (Baseline ) And After 1 Week, 6Week, 12 Week Of Treatment",Secondary Endpoint
412,NCT04977518,Infective Endocarditis,Not Mentioned,Not Mentioned,Not Mentioned,"During The Hospitalization, Average Of 1 Months",Primary Endpoint
413,NCT04977518,Infective Endocarditis,Not Mentioned,Not Mentioned,Not Mentioned,"During The Hospitalization, Average Of 1 Months",Primary Endpoint
414,NCT04977518,Infective Endocarditis,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
415,NCT04977505,Shoulder Dislocation,Hounsfield Unit Of Anchor Tunnel,Not Mentioned,Not Mentioned,2 Years After Surgery,Primary Endpoint
416,NCT04977505,Shoulder Dislocation,The Diameter Of Anchor Tunnel,Not Mentioned,Not Mentioned,2 Years After Surgery,Primary Endpoint
417,NCT04977505,Shoulder Dislocation,Hounsfield Unit,Not Mentioned,Ossification Site,2 Years After Surgery,Primary Endpoint
418,NCT04977505,Shoulder Dislocation,Unossified Area Of Anchor Tunnel,Not Mentioned,Not Mentioned,2 Years After Surgery,Secondary Endpoint
419,NCT04977505,Shoulder Dislocation,Ossification Quality Score,Not Mentioned,Not Mentioned,2 Years After Surgery,Secondary Endpoint
420,NCT04977440,Intensive Care Unit Syndrome,Not Mentioned,Not Mentioned,"Glycemic Control, Effect Of High Protein Intake",Up To 7 Days,Primary Endpoint
421,NCT04977440,Intensive Care Unit Syndrome,Not Mentioned,Not Mentioned,Effect Of High Protein Intake On Serum Electrolytes,Up To 7 Days,Primary Endpoint
422,NCT04977440,Intensive Care Unit Syndrome,Icu Outcome,Not Mentioned,Effect Of High Protein Intake,Up To 7 Days,Secondary Endpoint
423,NCT04977219,Stroke,Not Mentioned,Not Mentioned,Not Mentioned,Up To 55 Days,Primary Endpoint
424,NCT04977219,Stroke,Not Mentioned,Not Mentioned,Not Mentioned,Up To 55 Days,Secondary Endpoint
425,NCT04977219,Stroke,Not Mentioned,Not Mentioned,Not Mentioned,Up To 55 Days,Secondary Endpoint
426,NCT04977219,Stroke,Not Mentioned,Not Mentioned,Not Mentioned,Up To 55 Days,Secondary Endpoint
427,NCT04977011,"Diabetic Ketoacidosis, Heart Disease, Ischemic, Stroke, Gastrointestinal Bleeding, Acute Kidney Injury, Heart Failure, Trauma, Septic Shock, Respiratory Failure, Pneumonia, Intracerebral Hemorrhage, Head Injury, Liver Diseases",Not Mentioned,Not Mentioned,Not Mentioned,3Day,Primary Endpoint
428,NCT04977011,"Diabetic Ketoacidosis, Heart Disease, Ischemic, Stroke, Gastrointestinal Bleeding, Acute Kidney Injury, Heart Failure, Trauma, Septic Shock, Respiratory Failure, Pneumonia, Intracerebral Hemorrhage, Head Injury, Liver Diseases",Not Mentioned,Not Mentioned,Not Mentioned,3 Day,Secondary Endpoint
429,NCT04977011,"Diabetic Ketoacidosis, Heart Disease, Ischemic, Stroke, Gastrointestinal Bleeding, Acute Kidney Injury, Heart Failure, Trauma, Septic Shock, Respiratory Failure, Pneumonia, Intracerebral Hemorrhage, Head Injury, Liver Diseases",Not Mentioned,Not Mentioned,Not Mentioned,3 Day,Secondary Endpoint
430,NCT04976673,"Lichen Planus, Oral",Not Mentioned,Not Mentioned,Oral Lichen Planus,12 Weeks,Primary Endpoint
431,NCT04976673,"Lichen Planus, Oral",Not Mentioned,Not Mentioned,Not Mentioned,12 Weeks,Secondary Endpoint
432,NCT04976543,"Cirrhosis, Portal Vein Thrombosis, Esophageal Varices",Rebleeding,Not Mentioned,Not Mentioned,6-Week,Primary Endpoint
433,NCT04976543,"Cirrhosis, Portal Vein Thrombosis, Esophageal Varices",Not Mentioned,Not Mentioned,Death,6-Week,Secondary Endpoint
434,NCT04976504,"Desaturation Of Blood, Anesthesia",Not Mentioned,Not Mentioned,Additional Warning Time Provided,"From Time Of Starting Preoxygenation Until The Time Of Spo2 90%, Assessed Up To 20 Minutes",Primary Endpoint
435,NCT04976504,"Desaturation Of Blood, Anesthesia",Not Mentioned,"Correlation, Pao2","Correlation, Pao2","From Time Of Starting Preoxygenation Until The Time Of Spo2 90%, Assessed Up To 20 Minutes",Secondary Endpoint
436,NCT04976439,"Colorectal Cancer, Apc Gene Mutation, Tp53 Gene Mutation, Pik3Ca Gene Mutation, Kras Mutation-Related Tumors, Mlh1 Gene Mutation",Not Mentioned,Clinical Characteristics,Not Mentioned,January 2017 - June 2021,Primary Endpoint
437,NCT04976439,"Colorectal Cancer, Apc Gene Mutation, Tp53 Gene Mutation, Pik3Ca Gene Mutation, Kras Mutation-Related Tumors, Mlh1 Gene Mutation",Not Mentioned,Not Mentioned,Tumor Nature,January 2017 - June 2021,Primary Endpoint
438,NCT04976439,"Colorectal Cancer, Apc Gene Mutation, Tp53 Gene Mutation, Pik3Ca Gene Mutation, Kras Mutation-Related Tumors, Mlh1 Gene Mutation",Survival,Not Mentioned,Not Mentioned,January 2017 - June 2021,Primary Endpoint
439,NCT04976439,"Colorectal Cancer, Apc Gene Mutation, Tp53 Gene Mutation, Pik3Ca Gene Mutation, Kras Mutation-Related Tumors, Mlh1 Gene Mutation",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
440,NCT04976361,Prp,Not Mentioned,Not Mentioned,Not Mentioned,6 Months,Primary Endpoint
441,NCT04976361,Prp,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
442,NCT04976114,Anxiety,Not Mentioned,Not Mentioned,Anxiety Level,"Presurgery, Just The Moment Before To Surgery",Primary Endpoint
443,NCT04976114,Anxiety,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
444,NCT04976088,"Trauma Injury, Inflammation","Means ""Worst Pain Imaginable","Baseline, Treatment Start, Left Extreme Means ""No Pain = 0"" While, Rest","Baseline, Treatment Start, Left Extreme Means ""No Pain = 0"" While, Rest",72 Hours,Primary Endpoint
445,NCT04976088,"Trauma Injury, Inflammation",(Auc),"Area Under, Spid0-8D), Curve, Rest","Area Under, Spid0-8D), Curve, Rest",Day 4 And Day 8,Secondary Endpoint
446,NCT04976088,"Trauma Injury, Inflammation","(Including Patients' Home Measurements), From Day","Baseline, Scale, ""No Pain = 0"", Rest","Baseline, Scale, ""No Pain = 0"", Rest","Day 1, Day 2, Day 3, Day 4, Day 5,Day 6, Day 7, Day 8",Secondary Endpoint
447,NCT04976088,"Trauma Injury, Inflammation",Not Mentioned,"Time To Resolution Of Pain At Rest, Measured Through Vas Scale (Visual Analogue Scale 0-100 Mm, Where ""No Pain = 0"", Baseline","Time To Resolution Of Pain At Rest, Measured Through Vas Scale (Visual Analogue Scale 0-100 Mm, Where ""No Pain = 0"", Baseline",From Day 1 Until The Date Of Resolution Of Pain At Rest (Maximum Day 8),Secondary Endpoint
448,NCT04976088,"Trauma Injury, Inflammation",Vas Score (Visual Analogue,"Baseline, Scale, ""No Pain = 0"", Treatment Start","Baseline, Scale, ""No Pain = 0"", Treatment Start",Day 4 And Day 8,Secondary Endpoint
449,NCT04976088,"Trauma Injury, Inflammation",Movement),"Proportion, Baseline, ""No Pain = 0"", Scale, Decrease ≥ 50%, Treatment Start","Proportion, Baseline, ""No Pain = 0"", Scale, Decrease ≥ 50%, Treatment Start",Day 4,Secondary Endpoint
450,NCT04976088,"Trauma Injury, Inflammation",Not Mentioned,"Proportion, Patients That Used Rescue Medication (Paracetamol), Baseline","Proportion, Patients That Used Rescue Medication (Paracetamol), Baseline",From Baseline To Day 8,Secondary Endpoint
451,NCT04976088,"Trauma Injury, Inflammation",Not Mentioned,"Patient Diary, Rescue Medication Consumed, Baseline","Patient Diary, Rescue Medication Consumed, Baseline",From Baseline To Day 8,Secondary Endpoint
452,NCT04976088,"Trauma Injury, Inflammation",0:≥90%,"% Adhered; 3:<50% Adhered, % Adhered; 2:≥50%, Open Staff Member; Following, Plaster Detached, Patients","% Adhered; 3:<50% Adhered, % Adhered; 2:≥50%, Open Staff Member; Following, Plaster Detached, Patients","Day 1, Day 2, Day 3, Day 4, Day 5,Day 6, Day 7, Day 8",Secondary Endpoint
453,NCT04976088,"Trauma Injury, Inflammation",Not Mentioned,"Baseline, Auscultation, Physical Examination","Baseline, Auscultation, Physical Examination","Day 1, Day 2, Day3, Day 4, Day 5,Day 6, Day 7, Day 8",Secondary Endpoint
454,NCT04976088,"Trauma Injury, Inflammation",Not Mentioned,"Baseline, Measured In Mmhg, Blood Pressure","Baseline, Measured In Mmhg, Blood Pressure","Day 1, Day 2, Day3, Day 4, Day 5,Day 6, Day 7, Day 8",Secondary Endpoint
455,NCT04976088,"Trauma Injury, Inflammation",Not Mentioned,"Baseline, Measured In Mmhg, Blood Pressure","Baseline, Measured In Mmhg, Blood Pressure","Day 1, Day 2, Day3, Day 4, Day 5,Day 6, Day 7, Day 8",Secondary Endpoint
456,NCT04976088,"Trauma Injury, Inflammation",Not Mentioned,Baseline,Not Mentioned,"Day 1, Day 2, Day3, Day 4, Day 5,Day 6, Day 7, Day 8",Secondary Endpoint
457,NCT04976088,"Trauma Injury, Inflammation",Number Of Patient Withdrawals,Baseline,Not Mentioned,"Day 1, Day 2, Day3, Day 4, Day 5,Day 6, Day 7, Day 8",Secondary Endpoint
458,NCT04976088,"Trauma Injury, Inflammation",Number Of Adverse Events,Baseline,Not Mentioned,"Day 1, Day 2, Day3, Day 4, Day 5,Day 6, Day 7, Day 8",Secondary Endpoint
459,NCT04976088,"Trauma Injury, Inflammation",Not Mentioned,Not Mentioned,"Investigator, Local Tolerability (Erythema), Application Site",7=Strong Reaction Spreading Beyond Test Site,Secondary Endpoint
460,NCT04976088,"Trauma Injury, Inflammation",Not Mentioned,Not Mentioned,"Investigator, Local Tolerability, Application Site",3=Severe,Secondary Endpoint
461,NCT04976088,"Trauma Injury, Inflammation",Burning),Not Mentioned,"Investigator, Local Tolerability, Application Site",3=Severe,Secondary Endpoint
462,NCT04976088,"Trauma Injury, Inflammation",Not Mentioned,Not Mentioned,"Investigator, Local Tolerability, Local Pain), Application Site",3=Severe,Secondary Endpoint
463,NCT04976088,"Trauma Injury, Inflammation",Following Score,Not Mentioned,"Administration Site, Local Tolerability",8.,Secondary Endpoint
464,NCT04975971,"Anterior Chamber Inflammation, Ocular Pain, Corneal Edema, Corneal Defect, Penetrating Keratoplasty, Nuclear Cataract, Cortical Cataract, Cataract Senile",Mean Change In Pain Score,Not Mentioned,Not Mentioned,Assessed For 3 Months After Drug Insertion,Primary Endpoint
465,NCT04975971,"Anterior Chamber Inflammation, Ocular Pain, Corneal Edema, Corneal Defect, Penetrating Keratoplasty, Nuclear Cataract, Cortical Cataract, Cataract Senile",Flare) Scores,Not Mentioned,Not Mentioned,Assessed For 3 Months After Drug Insertion,Primary Endpoint
466,NCT04975971,"Anterior Chamber Inflammation, Ocular Pain, Corneal Edema, Corneal Defect, Penetrating Keratoplasty, Nuclear Cataract, Cortical Cataract, Cataract Senile",Not Mentioned,Not Mentioned,Not Mentioned,Assessed For 1 Months After Drug Insertion,Secondary Endpoint
467,NCT04975971,"Anterior Chamber Inflammation, Ocular Pain, Corneal Edema, Corneal Defect, Penetrating Keratoplasty, Nuclear Cataract, Cortical Cataract, Cataract Senile",Not Mentioned,Not Mentioned,Anterior Chamber Inflammation,Assessed For 3 Months After Drug Insertion,Secondary Endpoint
468,NCT04975971,"Anterior Chamber Inflammation, Ocular Pain, Corneal Edema, Corneal Defect, Penetrating Keratoplasty, Nuclear Cataract, Cortical Cataract, Cataract Senile",Eyes Requiring Additional,Proportion,Not Mentioned,Assessed For 3 Months After Drug Insertion,Secondary Endpoint
469,NCT04975971,"Anterior Chamber Inflammation, Ocular Pain, Corneal Edema, Corneal Defect, Penetrating Keratoplasty, Nuclear Cataract, Cortical Cataract, Cataract Senile",Number Of Patient Call-Backs Regarding,Not Mentioned,Not Mentioned,Assessed For 3 Months After Drug Insertion,Secondary Endpoint
470,NCT04975971,"Anterior Chamber Inflammation, Ocular Pain, Corneal Edema, Corneal Defect, Penetrating Keratoplasty, Nuclear Cataract, Cortical Cataract, Cataract Senile",Number Of Pharmacy Call-Backs Regarding,Not Mentioned,Not Mentioned,Assessed For 3 Months After Drug Insertion,Secondary Endpoint
471,NCT04975971,"Anterior Chamber Inflammation, Ocular Pain, Corneal Edema, Corneal Defect, Penetrating Keratoplasty, Nuclear Cataract, Cortical Cataract, Cataract Senile",Adverse Events,Not Mentioned,Not Mentioned,Assessed For 3 Months After Drug Insertion,Secondary Endpoint
472,NCT04975971,"Anterior Chamber Inflammation, Ocular Pain, Corneal Edema, Corneal Defect, Penetrating Keratoplasty, Nuclear Cataract, Cortical Cataract, Cataract Senile",Mean Change In Iop,Not Mentioned,Not Mentioned,Assessed For 3 Months After Drug Insertion,Secondary Endpoint
473,NCT04975971,"Anterior Chamber Inflammation, Ocular Pain, Corneal Edema, Corneal Defect, Penetrating Keratoplasty, Nuclear Cataract, Cortical Cataract, Cataract Senile",Change In Bcva,Not Mentioned,Not Mentioned,Assessed For 3 Months After Drug Insertion,Secondary Endpoint
474,NCT04975659,Communication,Pain Score,Not Mentioned,Not Mentioned,"Throughout Study Completion, Average Of 10 Months",Primary Endpoint
475,NCT04975659,Communication,Anxiety Score,Baseline,Not Mentioned,"Through Study Completion, Average Of 10 Months",Primary Endpoint
476,NCT04975659,Communication,Not Mentioned,Not Mentioned,Not Mentioned,"Through Study Completion, Average Of 10 Months",Primary Endpoint
477,NCT04975659,Communication,Anxiety Score,Not Mentioned,Not Mentioned,"Through Study Completion, Average Of 10 Months",Secondary Endpoint
478,NCT04975659,Communication,Anxiety Score,Not Mentioned,Not Mentioned,"Through Study Completion, Average Of 10 Months",Secondary Endpoint
479,NCT04975542,Respiratory Function Impaired,Change In Chest Wall Excursion,Not Mentioned,Not Mentioned,Measure Assessing A Change From Baseline Chest Wall Excursion Within 5 Minutes Of Treatment Completion.,Primary Endpoint
480,NCT04975542,Respiratory Function Impaired,Fvc),Not Mentioned,Not Mentioned,Measure Assessing A Change From Baseline Fvc Value Via Pulmonary Function Testing Within 5 Minutes Of Treatment Completion.,Primary Endpoint
481,NCT04975542,Respiratory Function Impaired,Change In Forced Expiratory Volume,Not Mentioned,Not Mentioned,1 Second,Primary Endpoint
482,NCT04975542,Respiratory Function Impaired,Fvc Ratio,Not Mentioned,Not Mentioned,Measure Assessing A Change From Baseline Fev1/Fvc Ratio Value Via Pulmonary Function Testing Within 5 Minutes Of Treatment Completion.,Primary Endpoint
483,NCT04975542,Respiratory Function Impaired,Change,Not Mentioned,Not Mentioned,Measure Assessing A Change From Baseline Respiratory Rate Within 5 Minutes Of Treatment Completion.,Secondary Endpoint
484,NCT04975542,Respiratory Function Impaired,Change In Heart Rate,Not Mentioned,Not Mentioned,Measure Assessing A Change From Baseline Heart Rate Within 5 Minutes Of Treatment Completion.,Secondary Endpoint
485,NCT04975542,Respiratory Function Impaired,Not Mentioned,Not Mentioned,Not Mentioned,Measure Assessing A Change From Baseline Oxygen Saturation Within 5 Minutes Of Treatment Completion.,Secondary Endpoint
486,NCT04975529,"Exercise, Diet",Mean Change,"Baseline, Patient-Reported Outcomes Measurement Information System (Promis","Baseline, Patient-Reported Outcomes Measurement Information System (Promis",6-Months,Primary Endpoint
487,NCT04975529,"Exercise, Diet",Physical Activity,Baseline,Not Mentioned,6-Months,Secondary Endpoint
488,NCT04975529,"Exercise, Diet",Mean Change,"Baseline, Vegetable Screener","Baseline, Vegetable Screener",6-Months,Secondary Endpoint
489,NCT04975529,"Exercise, Diet",Mean Change,"Baseline, Positive Youth Development (Pyd) Short Form Confidence Scale","Baseline, Positive Youth Development (Pyd) Short Form Confidence Scale",6-Months,Secondary Endpoint
490,NCT04975412,Acne Vulgaris,Not Mentioned,Not Mentioned,Not Mentioned,Initial Consult,Primary Endpoint
491,NCT04975412,Acne Vulgaris,Not Mentioned,Not Mentioned,Not Mentioned,Initial Consult,Primary Endpoint
492,NCT04975412,Acne Vulgaris,Not Mentioned,Demographics,Not Mentioned,Initial Consult,Secondary Endpoint
493,NCT04975360,"Sleep Inertia, Caffeine, Placebo",Not Mentioned,Not Mentioned,Not Mentioned,At 07:00 Hours After Caffeine And Placebo Administration,Primary Endpoint
494,NCT04975360,"Sleep Inertia, Caffeine, Placebo",Not Mentioned,Not Mentioned,Recording Of Nocturnal Sleep,Between 03:00-07:00 Hours After Caffeine And Placebo Administration,Secondary Endpoint
495,NCT04975360,"Sleep Inertia, Caffeine, Placebo",Not Mentioned,Not Mentioned,Caffeine Effects Questionnaire,Between 07:15-08:00 Hours After Caffeine And Placebo Administration,Secondary Endpoint
496,NCT04975360,"Sleep Inertia, Caffeine, Placebo",Not Mentioned,Not Mentioned,Not Mentioned,Between 07:00-08:15 Hours After Caffeine And Placebo Administration,Secondary Endpoint
497,NCT04975360,"Sleep Inertia, Caffeine, Placebo",Psychomotor Vigilance Task,Not Mentioned,Not Mentioned,Between 07:15-07:30 Hours After Caffeine And Placebo Administration,Secondary Endpoint
498,NCT04975360,"Sleep Inertia, Caffeine, Placebo",Not Mentioned,Not Mentioned,Not Mentioned,Between 07:30-07:40 Hours After Caffeine And Placebo Administration,Secondary Endpoint
499,NCT04975360,"Sleep Inertia, Caffeine, Placebo",D2 Attention Task,Not Mentioned,Not Mentioned,Between 07:40-07:45 Hours After Caffeine And Placebo Administration,Secondary Endpoint
500,NCT04975360,"Sleep Inertia, Caffeine, Placebo",Not Mentioned,Not Mentioned,Not Mentioned,Between 07:00-08:00 Hours After Caffeine And Placebo Administration,Secondary Endpoint
501,NCT04975360,"Sleep Inertia, Caffeine, Placebo",Not Mentioned,Not Mentioned,Recording Of Morning Nap Opportunity,Between 08:00-09:00 Hours After Caffeine And Placebo Administration,Secondary Endpoint
502,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Not Mentioned,Not Mentioned,Not Mentioned,24 Months,Primary Endpoint
503,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Not Mentioned,Not Mentioned,Positioning,24 Months,Primary Endpoint
504,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Proximal Contact,Not Mentioned,Not Mentioned,24 Months,Primary Endpoint
505,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Not Mentioned,Not Mentioned,Not Mentioned,24 Months,Primary Endpoint
506,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Not Mentioned,Not Mentioned,Not Mentioned,24 Months,Primary Endpoint
507,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Not Mentioned,Not Mentioned,Not Mentioned,24 Months,Primary Endpoint
508,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Crown,Not Mentioned,Not Mentioned,24 Months,Primary Endpoint
509,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Veneer/Composite,Integrity,Not Mentioned,24 Months,Primary Endpoint
510,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Secondary Caries,Not Mentioned,Not Mentioned,24 Months,Primary Endpoint
511,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",History Of Trauma,Not Mentioned,Not Mentioned,24 Months,Primary Endpoint
512,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Not Mentioned,Clinical Pulp Pathology,Not Mentioned,24 Months,Primary Endpoint
513,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Not Mentioned,Not Mentioned,Not Mentioned,24 Months,Primary Endpoint
514,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Not Mentioned,Not Mentioned,Not Mentioned,24 Months,Primary Endpoint
515,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
516,NCT04975282,"Preterm, Feeding, Bottle, Feeding Behavior, Feeding, Breast",Not Mentioned,Not Mentioned,Not Mentioned,"From Transition To Breastfeeding, Up To 1 Week.",Primary Endpoint
517,NCT04975282,"Preterm, Feeding, Bottle, Feeding Behavior, Feeding, Breast",Not Mentioned,Not Mentioned,Not Mentioned,"From Admission To Discharge, Up To 4 Weeks",Primary Endpoint
518,NCT04975282,"Preterm, Feeding, Bottle, Feeding Behavior, Feeding, Breast",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
519,NCT04975126,Cataract,Decisional Conflict Scale Score,Not Mentioned,Not Mentioned,Day Of Pre-Assessment Visit (1 Week Before Surgery),Primary Endpoint
520,NCT04975126,Cataract,Not Mentioned,Not Mentioned,Regret Scale Score,1 Month After Surgery,Primary Endpoint
521,NCT04975126,Cataract,Number Of Correctly Answered Questions Assessing Knowledge,Not Mentioned,Not Mentioned,Day Of Pre-Assessment Visit (1 Week Before Surgery),Primary Endpoint
522,NCT04975126,Cataract,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
523,NCT04975113,"Patellofemoral Pain Syndrome, Kinesiotape, Exercise, Strength",Change From Visual Analogue Pain Scale Score,Not Mentioned,Not Mentioned,6Th. Weeks,Primary Endpoint
524,NCT04975113,"Patellofemoral Pain Syndrome, Kinesiotape, Exercise, Strength",Change From Isokinetic Muscle Strength,Not Mentioned,Not Mentioned,6Th. Weeks,Primary Endpoint
525,NCT04975113,"Patellofemoral Pain Syndrome, Kinesiotape, Exercise, Strength",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
526,NCT04975048,"Healthy, Gen1 Gene Mutation",Not Mentioned,Not Mentioned,Not Mentioned,"Week 0, Week 4, Week 8, Week 16",Primary Endpoint
527,NCT04975048,"Healthy, Gen1 Gene Mutation",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
528,NCT04975022,"Pk, Pd, And Safety",Not Mentioned,Not Mentioned,Cmax,"Pre-Dose, 5,10,20,30,40,50,60,75,90,105,120,150,180,210,240,270,300, 330,360,420,480 Minutes；",Primary Endpoint
529,NCT04975022,"Pk, Pd, And Safety",Auc 0-8 H,Not Mentioned,Not Mentioned,"Pre-Dose, 5,10,20,30,45,10,20,30,40,50,60,75,90,105,120,150,180,210,240,270,300, 330,360,420,480 Minutes；",Primary Endpoint
530,NCT04975022,"Pk, Pd, And Safety",Not Mentioned,Not Mentioned,Not Mentioned,"Pre-Dose, 0-8 Hours",Primary Endpoint
531,NCT04975022,"Pk, Pd, And Safety",Not Mentioned,Not Mentioned,Not Mentioned,"Pre-Dose, 0-8 Hours",Primary Endpoint
532,NCT04975022,"Pk, Pd, And Safety",Not Mentioned,Not Mentioned,Not Mentioned,"Pre-Dose, 5,10,20,30,40,50,60,75,90,105,120,150,180,210,240,270,300,330,360,420,480 Minutes；",Secondary Endpoint
533,NCT04975022,"Pk, Pd, And Safety",Auc 0-2 H,Not Mentioned,Not Mentioned,"Pre-Dose, 5,10,20,30,40,50,60,75,90,105,120 Minutes",Secondary Endpoint
534,NCT04975022,"Pk, Pd, And Safety",Elimination Half-Life (T1/2),Not Mentioned,Insulin,"Pre-Dose, 5,10,20,30,40,50,60,75,90,105,120,150,180,210,240,270,300, 330,360,420,480 Minutes；",Secondary Endpoint
535,NCT04975022,"Pk, Pd, And Safety",Not Mentioned,"Insulin, Time","Insulin, Time",4 H,Secondary Endpoint
536,NCT04975022,"Pk, Pd, And Safety",Not Mentioned,"Insulin, Infinite Time, Time","Insulin, Infinite Time, Time","Pre-Dose, 5,10,20,30,45,10,20,30,40,50,60,75,90,105,120,150,180,210,240,270,300, 330,360,420,480 Minutes；",Secondary Endpoint
537,NCT04975022,"Pk, Pd, And Safety",Not Mentioned,Not Mentioned,Not Mentioned,"Pre-Dose, 0-2 Hours",Secondary Endpoint
538,NCT04975022,"Pk, Pd, And Safety",Not Mentioned,Not Mentioned,Not Mentioned,"Pre-Dose, 0-4 Hours",Secondary Endpoint
539,NCT04975022,"Pk, Pd, And Safety",Not Mentioned,Not Mentioned,Not Mentioned,"Pre-Dose, 0-8 Hours",Secondary Endpoint
540,NCT04974983,"Glioblastoma, Angiogenesis",Not Mentioned,Not Mentioned,Not Mentioned,15 Months,Primary Endpoint
541,NCT04974983,"Glioblastoma, Angiogenesis",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
